Brief: Paxmedica Initiates Clinical Program To Advance Pax-101 Towards FDA Submission
08/11/2022 15:29
Nov 8 (Reuters) - PaxMedica Inc PXMD.O :
* PAXMEDICA INITIATES CLINICAL PROGRAM TO ADVANCE PAX-101
TOWARDS
FDA SUBMISSION
* PAXMEDICA INC - FINAL STUDY RESULTS ARE EXPECTED IN FIRST
HALF
OF 2023
Source text for Eikon: ID:nGNX3PdNcK
Further company coverage: PXMD.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Kuvatris Therapeutics
See all newsBrief: PaxMedica Responds To Emergency Request For IV Suramin And Commits To Provide Immediate Access To PAX-101
PaxMedica rises on Malawi's request for access to sleeping sickness drug
Brief: Paxmedica Receives Emergency Request For Iv Suramin From African Health Ministry For Use In Treating Fatal Sleeping Sickness
Brief: PaxMedica Achieves Key Milestone In The Development Of PAX-101 And Provides Update On Potential NDA Submission
Brief: Paxmedica Announces Pricing Of $7.0 Million Public Offering